First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zhou J, Zheng R, Zhang S, et al. Gastric and esophageal cancer in China 2000 to 2030: recent trends and short-term predictions of the future burden. Cancer Med. 2022;11(8):1902–1912. doi: 10.1002/cam4.4586
   PubMed Web of Science ®Google Scholar
• Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi. 2023;45(3):212–220. doi: 10.3760/cma.j.cn112152-20220922-00647
   PubMedGoogle Scholar
• An L, Zheng R, Zeng H, et al. The survival of esophageal cancer by subtype in China with comparison to the United States. Int J Cancer. 2023;152(2):151–161. doi: 10.1002/ijc.34232
   PubMed Web of Science ®Google Scholar
• Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3(1):17048.
   PubMedGoogle Scholar
• Sohda M, Kuwano H. Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg. 2017;23(1):1–11. doi: 10.5761/atcs.ra.16-00162
   PubMed Web of Science ®Google Scholar
• Sheikh M, Roshandel G, McCormack V, et al. Current status and future prospects for esophageal cancer. Cancers (Basel). 2023;15(3):765.
   PubMed Web of Science ®Google Scholar
• Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992–1004. doi: 10.1016/j.annonc.2022.07.003
   PubMed Web of Science ®Google Scholar
• Hiramoto S, Kato K, Shoji H, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol. 2018;23(3):466–472. doi: 10.1007/s10147-018-1239-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen T, Fang JY. Burden of gastrointestinal cancers in China from 1990 to 2019 and projection through 2029. Cancer Lett. 2023;560:216127. doi: 10.1016/j.canlet.2023.216127
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi: 10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi: 10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022;40(3):277–288.e3. doi: 10.1016/j.ccell.2022.02.007
   PubMed Web of Science ®Google Scholar
• Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483–495. doi: 10.1016/S1470-2045(23)00108-0
   PubMed Web of Science ®Google Scholar
• National Bureau of statistics of China. Statistical bulletin of national economic and social development of the people’s Republic of China in2022. (2022). Available online at https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2022l( accessed Jun 19, 2023).
   Google Scholar
• Saluja R, Cheng S, Delos Santos KA, et al. Estimating hazard ratios from published Kaplan-Meier survival curves: a methods validation study. Res Synth Methods. 2019;10(3):465–475. doi: 10.1002/jrsm.1362
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(1):139. doi: 10.1186/1471-2288-11-139
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. PharmacoEconomics. 2014;32(2):101–108. doi: 10.1007/s40273-013-0123-9
   PubMed Web of Science ®Google Scholar
• YaoZH (2022). Drug pice. Available at: https://www.yaozh.com/ (Accessed Jun 19, 2023).
   Google Scholar
• Zhang Q, Wu P, He X, et al. Cost-effectiveness analysis of camrelizumab vs. Placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China. Front Oncol. 2021;11:790373. doi: 10.3389/fonc.2021.790373
   PubMed Web of Science ®Google Scholar
• Liu S, Dou L, Wang K, et al. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12:899966. doi: 10.3389/fonc.2022.899966
   PubMed Web of Science ®Google Scholar
• You M, Huang Y, Cai Z, et al. Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. Front Oncol. 2022;12:986762. doi: 10.3389/fonc.2022.986762
   PubMed Web of Science ®Google Scholar
• Gong J, Shang J, Su D, et al. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):1–9. doi: 10.1080/14737167.2023.2214732
   PubMed Web of Science ®Google Scholar
• Liu S, Jiang N, Dou L, et al. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol. 2023;14:1172242. doi: 10.3389/fimmu.2023.1172242
   PubMed Web of Science ®Google Scholar
• Zheng Z, Fang L, Cai H, et al. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):1–8. doi: 10.1080/14737167.2023.2206570
   PubMed Web of Science ®Google Scholar
• State Administration of Foreign Exchange (2022) Table of conversion rates of various currencies to USD. Available at: https://www.safe.gov.cn/safe/2023/0228/22399.html(Accessed Jun 19, 2023).
   Google Scholar
• Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1–5. doi: 10.1016/j.vhri.2020.07.580
   PubMedGoogle Scholar
• Zheng Z, Lin J, Zhu H, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. Chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and PD-L1 CPS of 10 or more. Front Public Health. 2022;10:893387. doi: 10.3389/fpubh.2022.893387
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Van Cutsem E, Oh SC, et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016;27(4):673–679. doi: 10.1093/annonc/mdv625
   PubMed Web of Science ®Google Scholar
• Lin MQ, Li YP, Wu SG, et al. Differences in esophageal cancer characteristics and survival between Chinese and caucasian patients in the SEER database. Onco Targets Ther. 2016;9:6435–6444. doi: 10.2147/OTT.S112038
   PubMed Web of Science ®Google Scholar
• Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789. doi: 10.1016/j.esmoop.2023.100789
   PubMedGoogle Scholar
• Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med. 2020;8(18):1193. doi: 10.21037/atm-20-4625
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29(2):473–482. doi: 10.1038/s41591-022-02179-2
   PubMed Web of Science ®Google Scholar
• Zhang H, Fu Y, Chen M, et al. Socioeconomic inequality in health care use among cancer patients in China: evidence from the China health and retirement longitudinal study. Front Public Health. 2022;10:942911. doi: 10.3389/fpubh.2022.942911
   PubMed Web of Science ®Google Scholar
• Thomson S, Everest L, Witzke N, et al. Examining the association between oncology drug clinical benefit and the time to public reimbursement. Cancer Med. 2022;11(2):380–391. doi: 10.1002/cam4.4455
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu R, Geng X, et al. The impact of national Centralised drug procurement policy on the use of policy-related original and generic drugs in China. Int J Health Plann Manage. 2022;37(3):1650–1662. doi: 10.1002/hpm.3429
   PubMed Web of Science ®Google Scholar
• Ding YF, Zhang JW, Xia MJ, et al. Availability and affordability of therapeutic monoclonal antibodies after the New medical reform in Hubei Province, China. Curr Med Sci. 2022;42(6):1325–1333. doi: 10.1007/s11596-022-2677-2
   PubMed Web of Science ®Google Scholar
• Cai L, Tao T, Li H, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J Glob Health. 2022;12:11016. doi: 10.7189/jogh.12.11016
   PubMed Web of Science ®Google Scholar
• Shi F, He Z, Su H, et al. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Front Pharmacol. 2022;13:961347. doi: 10.3389/fphar.2022.961347
   PubMed Web of Science ®Google Scholar
• Li L, Liu X, Huang J, et al. Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma. J Gastrointest Oncol. 2022;13(1):40–48. doi: 10.21037/jgo-21-870
   PubMed Web of Science ®Google Scholar
• Liu S, Dou L, Li S. Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China. Front Pharmacol. 2023;14:1055727. doi: 10.3389/fphar.2023.1055727
   PubMed Web of Science ®Google Scholar